9806087
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 7/06 — A1

(11) International Publication Number: WO 97/47276

(43) International Publication Date: 18 December 1997 (18.12.97)

(21) International Application Number: PCT/GB97/01542

(22) International Filing Date: 6 June 1997 (06.06.97)

(30) Priority Data:
9612108.2 10 June 1996 (10.06.96) GB

(71) Applicant *(for all designated States except US)*: BIO-SCIENTIFIC LIMITED [GB/GB]; 24 Harmont House, 20 Harley Street, London W1N 1AN (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: RUSHTON, David, Hugh [GB/GB]; Frogmoor Cottage, 61 Harefield Road, Rickmansworth, Hertfordshire WD3 1LZ (GB).

(74) Agent: ANDREWS, Timothy, Stephen; Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THE USE OF L-LYSINE IN THE TREATMENT OF HAIR LOSS

(57) Abstract

The use of L-lysine in the manufacture of a medicament for the prophylaxis and treatment of hair loss in humans, particularly telogen effluvium, is provided. A kit is also provided which includes a plurality of separate containers, each containing at least one active agent useful in a combination therapy for the treatment of genetic hair loss, wherein said kit includes L-lysine and at least further active agent selected from minoxidil, anti-androgens, 5α-reductase inhibitors, aromatase inhibitors and corticosteroids.